Featured Research

from universities, journals, and other organizations

Breast Cancer Vaccine Stimulates Potent Immune Response To Cancer Cells

Date:
April 18, 2007
Source:
Mayo Clinic
Summary:
Mayo Clinic researchers have designed a new strategy in the promising field of cancer vaccine research that's proven to be successful in boosting T cells -- the immune builders akin to a super defense force against cancer cells.

Mayo Clinic researchers have designed a new strategy in the promising field of cancer vaccine research that's proven to be successful in boosting T cells -- the immune builders akin to a super defense force against cancer cells. Scientists say their strategy may prove to be more successful than methods currently under study and in clinical trials.

Using vaccines to prevent or slow the growth of cancerous tumors is based on the premise that the body's immune system can be strengthened with an engineered vaccine that would stimulate an antibody and cellular response against cancer cells. Cancer vaccines are still considered experimental and so far, research results have been mixed. New studies, such as this, demonstrate that researchers are closing in on designing viable cancer vaccines, the investigators say.

In this study, Pilar Nava-Parada, M.D., Ph.D., and colleagues designed a synthetic peptide vaccine that stimulated an anti-tumor T cell response that recognized and successfully waged a battle against the spread of breast cancer cells in mouse models. (T cells are white blood cells with a key function in immune response.) Dr. Nava-Parada was a postdoctoral fellow in immunology at Mayo Clinic when she and Esteban Celis, M.D., Ph.D., began this research, which they planned to continue at Tulane University and Louisiana State University in New Orleans. But Hurricane Katrina struck before they had a chance to resume the research, so Dr. Nava-Parada returned to Mayo Clinic in Rochester where she began the research anew.

In female mouse models bred with the cancer-producing oncogene HER-2/neu, researchers administered a synthetic peptide vaccine during the early stage of tumor development. The experiment was effective in 100 percent of the study samples by either slowing or stopping the progression of breast cancer. In at least one case, the vaccine worked for as long as 39 weeks.

Because the use of synthetic peptides alone generally does not trigger a strong immune response, researchers administered the vaccine in combination with a Toll-like receptor stimulant that is designed to mimic the way in which an invading bacterial agent would induce an immune response in humans.

Under normal conditions, the response is generally strong enough for the body to recognize and attack invading bacteria. Researchers used this strategy, but also introduced anti-CD25 antibodies to increase the immune response. These antibodies control the production of T regulatory cells that can prevent the vaccine from doing its job, but by combining the two strategies (immunization and depletion of T regulatory mechanisms), the vaccine successfully passed through the T cell checkpoint. This approach was successful in stimulating an effective immune response.

"We found that we could train the immune system to recognize these synthetic peptides as dangerous foreign agents of the HER-2/neu gene by mimicking what the bacteria would do in your body. The body responded by killing everything that expressed HER-2/neu in high amounts," Dr. Nava-Parada said. In addition, "we estimate that in a real life scenario, we could probably use this technique to decrease the number of immunizations a patient would need (one instead of three), to build an immune response strong enough to destroy the tumor."

Dr. Nava-Parada said that up until now, researchers undertaking similar work have only been able to get vaccines to work in about 30 percent of HER-2/neu study models, but only by depleting T regulatory cells, which can have negative side effects, such as an autoimmune disorder. "In our study we showed that we can prevent tumors without depleting these cells and can achieve this success only by using a bacterial-like adjuvant administered with the right peptide," she said.

In addition, Dr. Nava-Parada said that other studies fail to accurately represent human cancers because they measure acute rejection of a tumor cell line that is produced in the laboratory and then injected into healthy animal models. Study models like the one described in this AACR presentation are thought to be more realistic because the study considers the entire natural history of the tumor in an animal that harbors the HER-2/neu gene.

"When the animal has a precancerous lesion, we vaccinate it and closely follow the appearance of the spontaneous tumor through its life. Conducting the research in this manner allows us to gain a clearer insight into a real-life cancer patient's situation," she said.

Cancer vaccines are intended for patients with a strong genetic predisposition or personal history of cancer; patients who do not respond to traditional therapies; or, as a preventive measure for patients who have successfully completed traditional courses of treatment, such as surgery, radiation and/or chemotherapy.

Cancer Vaccine Mouse Models and Research Data Lost in Hurricane Katrina

Dr. Nava-Parada was a post-doctoral fellow at Mayo Clinic where she worked in the laboratory of Esteban Celis, M.D., Ph.D., a specialist in immunology and cancer research pursuing the development of a vaccine to treat and prevent breast cancer. In November 2004, Drs. Celis and Nava-Parada moved the research from Minnesota to Louisiana where they planned to continue the work with Tulane University and Louisiana State University. But Hurricane Katrina struck before they could resume the research. The data and colony of mice developed for the study were destroyed.

"When I lost the work, I decided to return to Mayo where Dr. Larry Pease, Ph.D., (chief of immunology) graciously gave me space in his lab to continue this work," Dr. Nava-Parada said.

Rebuilding the colony of mice is a slow and tedious process, but the research team successfully re-established the colony in approximately 16 weeks.

The study's principal investigator is Esteban Celis, M.D., Ph.D., a specialist in immunology and cancer research, formerly of Mayo Clinic, but currently with H. Lee Moffitt Cancer Center & Research Institute in Florida. Other authors include: Larry Pease, Ph.D., and Keith Knutson, Ph.D., both of Mayo Clinic; and, Guido Forni of the University of Torino in Italy.

The research was supported with grants from the National Institutes of Health (Esteban Celis, M.D., Ph.D.), AACR (Pilar Nava-Parada, M.D., Ph.D.) and Mayo Clinic.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Breast Cancer Vaccine Stimulates Potent Immune Response To Cancer Cells." ScienceDaily. ScienceDaily, 18 April 2007. <www.sciencedaily.com/releases/2007/04/070417204001.htm>.
Mayo Clinic. (2007, April 18). Breast Cancer Vaccine Stimulates Potent Immune Response To Cancer Cells. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2007/04/070417204001.htm
Mayo Clinic. "Breast Cancer Vaccine Stimulates Potent Immune Response To Cancer Cells." ScienceDaily. www.sciencedaily.com/releases/2007/04/070417204001.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Beijing Marathon Runners Brave Hazardous Air Pollution

Beijing Marathon Runners Brave Hazardous Air Pollution

AFP (Oct. 19, 2014) Tens of thousands of runners battled thick smog at the Beijing Marathon on Sunday, with some donning masks as the levels of PM2.5 small pollutant particles soared to 16 times the maximum recommended level. Duration: 00:54 Video provided by AFP
Powered by NewsLook.com
Would A Travel Ban Even Work In Stopping Ebola Spread?

Would A Travel Ban Even Work In Stopping Ebola Spread?

Newsy (Oct. 19, 2014) The U.S. currently isn't banning travel from Ebola-stricken areas, but it's at least being considered. Some argue though it could be counterproductive. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins